Featured Content |View More
Roswell Park Earns ‘Exceptional’ Rating from National Cancer Institute With Best-Ever Core Grant
Region’s only Comprehensive Cancer Center earns maximum rating, marking five decades of consecutive NCI support.
Clinical Trial Mounts Two-Pronged Attack Against Relapsed/Refractory Pediatric Sarcomas
In recent years investigators have launched a growing number of clinical trials evaluating the efficacy of combining chemotherapy and immunotherapy in a two-pronged attack against cancer.
Both immune suppressive therapy (IST) and bone marrow transplant (BMT) are potentially curative for severe aplastic anemia (SAA). Currently BMT is the therapy of choice for young patients who have a matched sibling or other family donor; ...
A clinical trial underway at Roswell Park aims to expand treatment options patients with advanced refractory sarcoma with a novel approach to immunotherapy.
Pediatric Multicenter Study Shows Targeted Therapy for High-Risk Hodgkin Lymphoma Reduces Relapse
BUFFALO, N.Y. and ATLANTA, GA. — A targeted therapy for children with high-risk Hodgkin lymphoma (HL) was shown to significantly reduce relapse rates when tested in a large multicenter clinical trial conducted by the Children’s Oncology ...
From ASCO 2022: Brentuximab Vedotin and Chemotherapy an Effective Treatment for Hodgkin Lymphoma
Children’s Oncology Group study shows benefit for children and adolescents with high-risk HL treated with the combination
This site is intended for healthcare professionals